Acadia Pharmaceuticals' rare disease therapy fails late-stage trial

Core Insights - Acadia Pharmaceuticals announced that its experimental therapy for a rare metabolic condition did not achieve its primary endpoint in a late-stage clinical trial [1] Company Summary - Acadia Pharmaceuticals is focused on developing treatments for rare metabolic conditions [1] - The failure of the therapy in the late-stage study may impact the company's future research and development strategies [1]